Cerevel Therapeutics Holdings, Inc.
CEREDelisted Aug 1, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001805387
Cerevel Therapeutics Holdings, Inc. was delisted on Aug 1, 2024; its insiders filed their last Form 4 on Aug 5, 2024; 231 institutions reported holding it in 13F filings for Q2 2024, worth $6.42B in total; Soros Fund Management was the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Cerevel Therapeutics Holdings, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Cerevel Therapeutics Holdings, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Bain Capital Investors LLC | Director, 10% Owner | 0Indirect | Aug 5, 2024 | 0 |
| Bain Capital Fund XII, LP | Director, 10% Owner | 0Indirect | Aug 5, 2024 | 0 |
| BCPE Perception GP, LLC | Director, 10% Owner | 0Indirect | Aug 5, 2024 | 0 |
| BC Perception Holdings, LP | Director, 10% Owner | 0Indirect | Aug 5, 2024 | 0 |
| Bain Capital Partners XII, LLC | Director, 10% Owner | 0Indirect | Aug 5, 2024 | 0 |
| Pfizer Inc | Other: Former 10% Owner | 0 | Aug 5, 2024 | 0 |
| Patrick Deval L | Director | 0 | Aug 5, 2024 | 0 |
| Riedel Norbert G | Director | 0 | Aug 5, 2024 | 0 |
| Coles N Anthony | Director | 0 | Aug 5, 2024 | 0 |
| Dekkers Marijn E | Director | 0Indirect | Aug 5, 2024 | 0 |
| Sulzberger Gabrielle | Director | 0 | Aug 5, 2024 | 0 |
| Renaud Ronald C JR | President & CEO | 0Indirect | Aug 5, 2024 | 0 |
| Giordano Douglas E. | Director | 0 | Aug 5, 2024 | 0 |
| Gordon Christopher R | Director, 10% Owner | 0Indirect | Aug 5, 2024 | 0 |
| Mckernan Ruth | Director | 0 | Aug 5, 2024 | 0 |
| DiPietro Kenneth | Chief Human Resources Officer | 0 | Aug 5, 2024 | 0 |
| Koppel Adam | Director, 10% Owner | 0Indirect | Aug 5, 2024 | 0 |
| Burgess Paul D. | See Remarks | 0 | Aug 5, 2024 | 0 |
| Akamine Scott | Chief Legal Officer | 0 | Aug 5, 2024 | 0 |
| ALTSCHULLER Susan | Chief Financial Officer | 0 | Aug 5, 2024 | 0 |
| Sanchez Ramiro | Chief Medical Officer | 0 | Aug 5, 2024 | 0 |
| Renger John | Chief Scientific Officer | 0 | Aug 5, 2024 | 0 |
| Bodenrader Mark | See Remarks | 0 | Aug 5, 2024 | 0 |
| Tregoning Kathleen | See Remarks | 0 | Aug 5, 2024 | 0 |
| Edelman Joseph | Director | 0Indirect | Feb 21, 2024 | 0 |
| Perceptive Advisors LLC | Director | 0Indirect | Feb 21, 2024 | 0 |
| Perceptive Life Sciences Master Fund Ltd | Director | 0Indirect | Feb 21, 2024 | 0 |
| Ceesay Abraham | President | 0 | Feb 8, 2023 | 0 |
| PF Equity Holdings 1 B.V. | 10% Owner | 0 | Apr 4, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 9, 2022 (view filing) | Aug 5-8 | 4 days | Renger JohnChief Scientific Officer | SSale | −30.0K | $34.25 | −$1.03M | −91.7%2.70K after | 2 lots |
| Aug 9, 2022 (view filing) | Aug 8 | 1 day | Akamine ScottChief Legal Officer | SSale | −10.0K | $40.00 | −$400.0K | −100.0%0 after | |
| Aug 9, 2022 (view filing) | Aug 5-8 | 4 days | Ceesay AbrahamPresident | SSale | −57.6K | $34.54 | −$1.99M | −100.0%0 after | 3 lots |
| Jul 22, 2022 (view filing) | Jul 20 | 2 days | Renger JohnChief Scientific Officer | SSale | −25.0K | $30.00 | −$750.0K | −90.2%2.70K after | |
| Jul 7, 2022 (view filing) | Jul 5-6 | 2 days | Renger JohnChief Scientific Officer | SSale | −26.1K | $30.11 | −$785.9K | −90.6%2.70K after | 2 lots |
| Apr 15, 2022 (view filing) | Apr 13 | 2 days | Renger JohnChief Scientific Officer | SSale | −45.0K | $34.65 | −$1.56M | −95.8%1.98K after | |
| Mar 31, 2022 (view filing) | Mar 29 | 2 days | Renger JohnChief Scientific Officer | SSale | −10.0K | $35.00 | −$350.0K | −83.5%1.98K after | |
| Mar 18, 2022 (view filing) | Mar 16-18 | 2 days | Renger JohnChief Scientific Officer | SSale | −45.0K | $31.11 | −$1.40M | −95.8%1.98K after | 2 lots |
| Mar 11, 2022 (view filing) | Mar 9 | 2 days | Renger JohnChief Scientific Officer | SSale | −30.0K | $33.33 | −$1.00M | −93.8%1.98K after | 2 lots |
| Mar 4, 2022 (view filing) | Mar 2 | 2 days | Renger JohnChief Scientific Officer | SSale | −25.0K | $30.00 | −$750.0K | −92.7%1.98K after | |
| Feb 11, 2022 (view filing) | Feb 9 | 2 days | Renger JohnChief Scientific Officer | SSale | −25.0K | $30.00 | −$750.0K | −92.7%1.98K after | |
| Dec 28, 2021 (view filing) | Dec 23-27 | 5 days | Renger JohnChief Scientific Officer | SSale | −10.0K | $35.00 | −$350.0K | −83.5%1.98K after | 2 lots |
| Dec 23, 2021 (view filing) | Dec 21 | 2 days | Renger JohnChief Scientific Officer | SSale | −7.30K | $32.50 | −$237.3K | −78.7%1.98K after | |
| Dec 17, 2021 (view filing) | Dec 15-17 | 2 days | Renger JohnChief Scientific Officer | SSale | −37.7K | $30.86 | −$1.16M | −95.0%1.98K after | 3 lots |
| Nov 15, 2021 (view filing) | Nov 10 | 5 days | Renger JohnChief Scientific Officer | SSale | −55.0K | $39.86 | −$2.19M | −100.0%0 after | 5 lots |
| Aug 31, 2021 (view filing)2:15 PM ET | Aug 26 | 5 daysLate | Edelman Joseph and 2 othersDirector | PPurchase | +68.0K | $30.23 | +$2.06M | +1.4%5.09M after | |
| Aug 25, 2021 (view filing)7:14 PM ET | Aug 23-25 | 2 days | Edelman Joseph and 2 othersDirector | PPurchase | +175.6K | $27.53 | +$4.83M | +3.6%5.02M after | 3 lots |
| Jul 9, 2021 (view filing)6:39 PM ET | Jul 7 | 2 days | Edelman Joseph and 2 othersDirector | PPurchase | +200.0K | $25.00 | +$5.00M | +4.3%4.84M after |